Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1991 Jun;82(6):716-23.
doi: 10.1111/j.1349-7006.1991.tb01908.x.

Interleukin-2-inducible killer activity and its regulation by blood monocytes from autologous lymphocytes of lung cancer patients

S Sone  1 , E Kunishige, F Fawzy, H Yanagawa, A Nii, K Maeda, S Atagi, Y Heike, Y Nishioka, K Mizuno, et al.
Affiliations

Interleukin-2-inducible killer activity and its regulation by blood monocytes from autologous lymphocytes of lung cancer patients

S Sone et al. Jpn J Cancer Res. 1991 Jun.

Abstract

The ability of blood lymphocytes of newly diagnosed lung cancer patients to respond to interleukin 2 (IL-2) to become IL-2-activated killer (LAK) cells and its regulation by autologous monocytes were examined. LAK activity was measured by 51Cr release assay. The abilities of lymphocytes among blood mononuclear cells (MNC) of subjects of different ages without malignancies to generate LAK activity against NK-cell resistant Daudi cells and lung adenocarcinoma (PC-9) cells were very similar. The LAK activity of blood MNC of lung cancer patients was also nearly the same as that of blood MNC of control subjects. There was no significant difference in IL-2-inducible LAK activity between MNC of patients with small cell lung cancer (SCLC) and those of patients with non-SCLC. Monocytes and lymphocytes were separated from blood MNC on a one-step Percoll gradient. Monocytes of lung cancer patients were found to augment in vitro induction of LAK activity by IL-2 of autologous blood lymphocytes. In contrast, endotoxin-stimulated monocytes suppressed LAK induction of autologous lymphocytes of cancer patients. These findings suggest that administration of IL-2 and LAK cells induced in vitro may be of benefit in the treatment of lung cancer.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. ) Grimm , E. A. , Mazumder , A. , Zhang , H. Z. and Rosenberg , S. A.Lymphokine‐activated killer cell phenomenon. Lysis of natural killer‐resistant fresh solid tumor cells by interleukin‐2 activated autologous human peripheral blood lymphocytes . J. Exp. Med. , 155 , 1823 – 1841 ( 1982. ). - PMC - PubMed
    1. ) Fujita , J. , Saijo , N. , Sasaki , Y. , Futami , H. , Ishihara , J. , Takahashi , H. , Hoshi , A , and Hamburger , A , Detection of cytotoxicity of freshly obtained lymphocytes and of lymphocytes activated with recombinant interleukin II (rIL‐2) against lung cancer cell lines by human tumor clonogenic assay (HTCA) . Eur. J. Cancer Clin Oncol , 22 , 445 – 450 ( 1986. ). - PubMed
    1. ) Rosenberg , S. A. , Lotze , M. T. , Muul , L. M. , Chang , A. E. , Avis , F. P. , Leitman , S. , Linehan , W. M. , Robertson , C. N. , Lee , R. E. , Rubin , J. T. , Seipp , C. A. , Simpson , C. G. and White , D. E. Aprogress report of the treatment of 157 patients with advanced cancer using lymphokine‐activated killer cells and interleukin‐2 or high‐dose of interleukin 2 alone . N. Engl. J. Med. , 316 , 889 – 897 ( 1987. ). - PubMed
    1. ) West , W. H , Tauer , K. W. , Yannelli , J. R. , Marshall , G. D. , Orr , D. W. , Thurman , G. B. and Oldham , R. K.Constant‐infusion recombinant interleukin‐2 in adoptive immunotherapy of advanced cancer . N. Engl. J. Med. , 316 , 898 – 905 ( 1987. ). - PubMed
    1. ) Itoh , K. , Tidlen , A. B. and Balch , C. M.Role of interleukin‐2 and a serum suppressive factor on the induction of activated killer cell cytotoxicity for human melanoma cells . Cancer Res. , 45 , 3173 – 3178 ( 1985. ). - PubMed

Publication types

LinkOut - more resources